Kamaroopin
Overview
Kamaroopin is a growth equity firm focused on building long-lasting companies, positioned to benefit from secular trends in consumer habits. Its purpose is to accelerate the growth of companies, combining dreams, capital and talent at the service of entrepreneurship, innovation and corporate legacy. It operates under a collaborative approach in the elaboration of proprietary investment theses, robust diligence and investment underwriting processes and in partnership with talented entrepreneurs and teams.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Petlove | Sep 2022 | Series C Extension | Co-investor |
| Conexa Saúde | Dec 2023 | Early Funding | Co-investor |
| Dr. Consulta | Aug 2023 | Series D Extension | Co-investor |
For institutional investors. Book with your work email.
Key People
Bruno Tupinamba
Co- Founder & Growth Investment
Pedro Faria
Founder and CIO
Talita Lacerda
Co-Founder
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Kamaroopin based?
Kamaroopin is headquartered in Brazil.
When was Kamaroopin founded?
Kamaroopin was founded in 2018.
How many portfolio companies does Kamaroopin have?
Kamaroopin has 4 portfolio companies in Caplight's dataset.
What are some companies in Kamaroopin's portfolio?
Portfolio companies visible on Caplight include Petlove, Conexa Saúde, Dr. Consulta.
What was Kamaroopin's most recent investment shown here?
Kamaroopin's most recent investment in this portfolio sample was in Conexa Saúde in 2023.
What sectors does Kamaroopin focus on?
Kamaroopin focuses on Healthcare & Life Sciences, Consumer & Commerce, Healthcare & Life Sciences, Enterprise Software, FinTech, Enterprise Software, Healthcare & Life Sciences, Consumer & Commerce.
What company stages does Kamaroopin focus on?
Stage focus information for Kamaroopin is not publicly available.
What is Kamaroopin's AUM?
Kamaroopin's assets under management are estimated between $100.0M and $250.0M.